Medicare Price Negotiations Expand to 30 More Drugs, Including Top Insulins

Federal health officials announced the fourth round of Medicare drug-price negotiations Tuesday, adding 30 medicines — including two widely used insulin products and a blockbuster anticoagulant — to the program. The selected drugs account for roughly a quarter of Part D spending and are used by an estimated 11 million beneficiaries.

Advocates for the program point to accumulating evidence that negotiation works. Prices agreed in the first two cycles came in an average of 44 percent below list, and the Congressional Budget Office now scores the program as saving $161 billion over ten years — more than its original estimate.

Patient groups emphasize the human ledger behind the numbers. Surveys before the program began found one in five seniors on insulin rationing doses; the $35 monthly cap and negotiated prices have measurably reduced skipped prescriptions, according to claims analyses published this spring.

The pharmaceutical industry continues to challenge the program in court, so far without success, and warns that revenue pressure will thin pipelines for hard diseases. Program supporters respond that manufacturers’ own investor disclosures project robust research budgets, and that taxpayers who fund early-stage science deserve prices reflecting that public contribution.

Negotiated prices for the new cohort take effect in 2029. Health economists say the more consequential fight is already visible on the horizon: whether to extend negotiated prices beyond Medicare to the employer-insured market, where list prices continue to climb.